Sun Pharma’s arm enters into licensing agreement with Aclaris Therapeutics, Inc.

06 Dec 2023 Evaluate

Sun Pharmaceutical Industries’ subsidiary -- Sun Pharmaceutical Industries, Inc. has entered into licensing agreement with Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases.

Under the license agreement, Aclaris granted Sun Pharma exclusive rights under certain patents for the use of deuruxolitinib, Sun Pharma’s JAK inhibitor, or other isotopic forms of ruxolitinib, to treat alopecia areata (AA) or androgenetic alopecia (AGA). The agreement includes an upfront payment of $15 million, regulatory and commercial milestones, and royalties.

Sun Pharmaceutical Industries is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company.


Sun Pharma Inds. Share Price

1828.00 -9.30 (-0.51%)
09-Jan-2025 15:28 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1828.00
Dr. Reddys Lab 1372.55
Cipla 1490.20
Lupin 2252.00
Zydus Lifesciences 1008.75
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.